Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP)

Thrombosis and Haemostasis

Volumn 113, Issue 4, 2015, Pages 870-880

  Subramaniam, Saravanan ^a   Thielmann, Ina ^b   Morowski, Martina ^b   Pragst, Ingo ^c   Sandset, Per Morten ^d   Nieswandt, Bernhard ^b   Etscheid, Michael ^e   Kanse, Sandip M ^a,d  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c CSL BEHRING GMBH   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Coagulation; Fibrinolysis; FSAP; HABP2; Haemostasis; Thrombosis

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CERULOPLASMIN; COLLAGEN; FACTOR VII ACTIVATING PROTEASE; FERRIC CHLORIDE; HEMOGLOBIN; PLASMA KALLIKREIN; PROTEINASE; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; CHLORIDE; FERRIC ION; FSAP PROTEIN, MOUSE; HABP2 PROTEIN, HUMAN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; NORADRENALIN; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD ANALYSIS; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; ENZYME ASSAY; HEMOSTASIS; HISTOLOGY; LIGAND BLOTTING; LUNG EMBOLISM; MESENTERIC ARTERIOLE THROMBOSIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TAIL BLEEDING TEST; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; WESTERN BLOTTING; ANIMAL; BLOOD; BLOOD CLOTTING TEST; C57BL MOUSE; CAROTID ARTERY; CAROTID ARTERY DISEASES; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; JUGULAR VEIN; KNOCKOUT MOUSE; MESENTERIC ARTERY; MESENTERIC VASCULAR OCCLUSION; PHENOTYPE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION TESTS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHLORIDES; COLLAGEN; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; GENETIC PREDISPOSITION TO DISEASE; HEMOSTASIS; JUGULAR VEINS; LIPOPROTEINS; MESENTERIC ARTERIES; MESENTERIC VASCULAR OCCLUSION; MICE, INBRED C57BL; MICE, KNOCKOUT; NOREPINEPHRINE; PHENOTYPE; SERINE ENDOPEPTIDASES; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84931275511     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0519     Document Type: Article

References (31)

1. Romisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002; 383: 1119-1124.
2. Kanse SM, Parahuleva M, Muhl L, et al. Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 2008; 99: 286-289.
3. Etscheid M, Kress J, Seitz R, et al. The hyaluronic acid-binding protease: a novel vascular and inflammatory mediator? Int Immunopharmacol 2008; 8: 166-170.
4. Stephan F, Hazelzet JA, Bulder I, et al. Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit Care 2011; 15: R110.
5. Zeerleder S, Zwart B, te Velthuis H, et al. Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP). FASEB J 2008; 22: 4077-4084.
6. Yamamichi S, Fujiwara Y, Kikuchi T, et al. Extracellular histone induces plasma hyaluronan-binding protein (factor VII activating protease) activation in vivo. Biochem Biophys Res Commun 2011; 409: 483-488.
7. Kanse SM, Gallenmueller A, Zeerleder S, et al. Factor VII-activating protease is activated in multiple trauma patients and generates anaphylatoxin C5a. J Immunol 2012; 188: 2858-2865.
8. Etscheid M, Muhl L, Pons D, et al. The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity. Thromb Res 2012; 130: 935-941.
9. Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, et al. Factor seven activating protease (FSAP): does it activate factor VII? J Thromb Haemost 2012; 10: 859-866.
10. Kanse SM, Declerck PJ, Ruf W, et al. Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. Arterioscl Thromb Vasc Biol 2012; 32: 427-433.
11. Stephan F, Dienava I, Bulder I, et al. Tissue factor pathway inhibitor is an inhibitor of Factor VII-activating protease. J Thromb Haemost 2012; 10: 7.
12. Roemisch J, Feussner A, Nerlich C, et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinol 2002; 13: 433-441.
13. Sedding D, Daniel JM, Muhl L, et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006; 203: 2801-2807.
14. Willeit J, Kiechl S, Weimer T, et al. Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667-670.
15. Wasmuth HE, Tag CG, Van de Leur E, et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 2009; 49: 775-780.
16. Trompet S, Pons D, Kanse SM, et al. Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Res Treatm 2011; 2011: 424759.
17. Hoppe B, Tolou F, Radtke H, et al. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549-1551.
18. Ahmad-Nejad P, Dempfle CE, Weiss C, et al. The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events. Thromb Res 2012; 130: 441-444.
19. van Minkelen R, de Visser MC, Vos HL, et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005; 105: 4898.
20. Gulesserian T, Hron G, Endler G, et al. Marburg I polymorphism of factor VIIactivating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006; 95: 65-67.
21. Franchi F, Martinelli I, Biguzzi E, et al. Marburg I polymorphism of factor VIIactivating protease and risk of venous thromboembolism. Blood 2006; 107: 1731.
22. Pecheniuk NM, Elias DJ, Xu X, et al. Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thromb Haemost 2008; 99: 453-455.
23. Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VIIactivating protease and the risk of venous thromboembolism. Thromb Haemost 2007; 97: 870-872.
24. Borkham-Kamphorst E, Zimmermann HW, Gassler N, et al. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. J Hepatol 2013; 58: 104-111.
25. Maroney SA, Ferrel JP, Pan S, et al. Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost 2009; 7: 1106-1113.
26. Girard TJ, Tuley E, Broze GJ, Jr. TFPIbeta is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood 2012; 119: 1256-1262.
27. Broze GJ, Jr., Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012; 17: 262-280.
28. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010; 16: 887-896.
29. Vincent LM, Tran S, Livaja R, et al. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. J Clin Invest 2013; 123: 3777-3787.
30. Wood JP, Bunce MW, Maroney SA, et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013; 110: 17838-17843.
31. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscl Thromb Vasc Biol 2007; 27: 2079-2093.